drugset / Trial / NCT04114539

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

NCT04114539

Phase 2 Completed 124 enrolled Emalex Biosciences Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study was an international, multicenter, open-label, long term extension study evaluating the safety of ecopipam tablets for the treatment of children and adolescent subjects with Tourette Syndrome.

Timeline

Start
2019-10-04
Primary completion
2022-11-11
Completion
2022-11-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ecopipam Small molecule 2 mg/kg Oral

Indications